Biogen Inc

Biogen’s latest update reveals EMA approval for high‑dose nusinersen and new natural‑history data on Dravet syndrome, highlighting breakthrough gene‑editing and ASO pipelines that could transform rare neurological care.

Biogen Inc. has secured regulatory approval in China for its investigational Alzheimer’s therapy, LEQEMBI, marking a significant milestone for the company’s Alzheimer’s portfolio and positioning it to capture a share of the growing market in China.

Biogen has exceeded analyst expectations in its Q2 performance, prompting a revised FY25 outlook and making its stock an attractive option for investors.

Biogen’s ZURZUVAE has been recommended for marketing authorization in the treatment of postpartum depression, marking a major breakthrough for the company and potentially boosting its stock price.

Biogen is making significant strides in Alzheimer’s research and beyond, presenting pivotal data on its treatment lecanemab and partnering with Stoke Therapeutics to tackle rare genetic disorders.

Biogen Inc. is poised to make significant strides in neurology and manufacturing, with a $2 billion investment in its North Carolina facility and a major scientific breakthrough in Alzheimer’s disease treatment.

Biogen’s financial performance has been marked by volatility, with its stock price fluctuating wildly over the past year, raising questions about its future prospects.

Biogen Inc’s stock price rose 4.03% on July 1 due to the initiation of a Phase 3 study for its treatment felzartamab.

Biogen has initiated a Phase 3 study to evaluate its investigational drug felzartamab for treating primary membranous nephropathy, a rare and debilitating kidney disease.

Biogen Inc. has initiated a Phase 3 pediatric study of omaveloxolone to treat Friedreich ataxia in children aged 2-15 years old.